Ardana Bioscience of Scotland, which focuses on reproductive healthproducts, has received a L2 million ($2.8 million) funding boost from a founder shareholder, UK Medical Ventures Fund. This brings to L3.1 million the amount raised by Ardana since it was established in the middle of 2000.
Chief executive Simon Best said that the additional funding will enable Ardana "to accelerate our most promising research initiatives, some of which have the potential to enter clinical trials within the next two years." He added that the firm will look to establish collaborations "with relevant industry players" in the near future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze